rethinkPeptides Search
Menu
Research citation

Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

What the researchers found

HRQoL improved in global quality of life, role, social, and emotional functioning.

Why it matters

Improving HRQoL is crucial for cancer patients, as it directly impacts their overall well-being and treatment satisfaction. These findings can guide personalized care approaches.

How the study worked

The study involved 204 NET patients who completed HRQoL questionnaires before and after up to four cycles of PRRT, with results compared to a reference population.

What this study cannot tell us

The study may not account for all variables affecting HRQoL and was limited to a specific patient population.

Read the original research

Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours.

Journal of neuroendocrinology, 35(10), e13342

Citation

Edfeldt, Katarina; Hellman, Per; Granberg, Dan; Lagergren, Pernilla; Thiis-Evensen, Espen; Sundin, Anders; Andersson, Camilla. (2023). Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours.. Journal of neuroendocrinology, 35(10), e13342. https://doi.org/10.1111/jne.13342